メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
寺井 秀樹
医学部腫瘍センター
ウェブサイト
https://k-ris.keio.ac.jp/html/100002690_ja.html
h-index
2300
被引用数
24
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2005
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(88)
類似のプロファイル
(6)
フィンガープリント
Hideki Teraiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Non Small Cell Lung Cancer
93%
Cohort Study
65%
Disease
58%
Epidermal Growth Factor Receptor
55%
Coronavirinae
54%
Symptom
37%
Osimertinib
36%
Combination Therapy
27%
Biological Marker
25%
Prospective Cohort Study
24%
Adverse Event
23%
Infection
23%
Malignant Neoplasm
21%
Chronic Obstructive Lung Disease
21%
Dyspnea
19%
Asthma
18%
SARS Coronavirus
18%
Discoidin Domain Receptor 2
18%
Irinotecan
18%
Diseases
18%
Overall Survival
17%
Progression Free Survival
17%
Chemotherapy
13%
Lung Tumor
13%
Observational Study
13%
Phase II Trials
12%
Gefitinib
11%
Mouse Model
10%
Monotherapy
10%
Pharmacokinetics
9%
Cytotoxic Chemotherapy
9%
Nedaplatin
9%
Afatinib
9%
Effusion
9%
Long Term Exposure
9%
Active Metabolite
9%
Intrinsic Resistance
9%
Cetuximab
9%
6 [4 (4 Ethyl 1 Piperazinylmethyl)phenyl] 4 (Alpha Methylbenzylamino) 7h pyrrolo[2,3 D]pyrimidine
9%
Bromodomain Inhibitor
9%
RNA-Sequencing
9%
Pembrolizumab
9%
Genetically Engineered Mouse Strain
9%
Immunotherapy
9%
ABC Transporter
9%
Nuclease
9%
Erlotinib
9%
Paclitaxel
9%
Vaccination Policy
9%
Medicine and Dentistry
Lung Cancer
75%
Non Small Cell Lung Cancer
69%
COVID-19
56%
Computer Assisted Tomography
41%
Epidermal Growth Factor Receptor
31%
Biological Marker
29%
Cohort Analysis
27%
Lung Adenocarcinoma
27%
Immune Checkpoint Inhibitor
23%
Retrospective Cohort Study
19%
Coronavirinae
18%
Diseases
18%
Artificial Respiration
16%
Overall Survival
16%
Cancer Cell
16%
Neoplasm
15%
Disease
15%
Dyspnea
15%
Targeted Therapy
15%
Elderly Patient
14%
Malignant Neoplasm
12%
Sequela
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Lung Cancer Cell Line
12%
Diarrhea
12%
Diagnosis
10%
Pemetrexed
10%
Bevacizumab
10%
Disease Severity
10%
Molecularly Targeted Therapy
10%
Multivariate Analysis
9%
Odds Ratio
9%
Cytotoxic Chemotherapy
9%
Atezolizumab
9%
Prospective Cohort Study
9%
Adverse Event
9%
Oncogene
9%
Auditory Hallucination
9%
Glycyrrhizic Acid
9%
Organizing Pneumonia
9%
Distress Syndrome
9%
Mediator
9%
Nedaplatin
9%
Organoid
9%
Adaptive Response
9%
Swallowing Function
9%
Hypocalcaemia
9%
Discoidin Domain Receptor 2
9%
Solid Malignant Neoplasm
9%
Postcovid Syndrome
9%
Keyphrases
COVID-19
43%
Long COVID
39%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
36%
Japan
35%
Confidence Interval
33%
Non-small Cell Lung Cancer (NSCLC)
31%
Non-small Cell Lung Cancer Patients
25%
Multicenter Cohort Study
22%
Osimertinib
18%
Combination Therapy
18%
Chest CT
18%
Dyspnea
16%
Long COVID Symptoms
15%
Immune Checkpoint Inhibitors
15%
Adjusted Odds Ratio
15%
Mechanical Ventilation
15%
Odds Ratio
14%
EGFR mutation
13%
Disease Severity
12%
Clinical Characteristics
12%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
12%
Previously Treated Patients
11%
Phase II Trial
11%
Chemotherapy
11%
Risk Factors
10%
Long Coronavirus Disease
10%
Retrospective Cohort Study
10%
Clinical Efficacy
9%
Japanese Patients
9%
Lung Cancer
9%
Diarrhea
9%
Synergistic Efficacy
9%
FOXD1
9%
Phase I Study
9%
Longitudinal Assessment
9%
COVID-19 Sequelae
9%
Benign Pulmonary Diseases
9%
Erlotinib
9%
Exon 20 mutation
9%
Nedaplatin
9%
Afatinib
9%
CPT-11
9%
Oncomine Dx Target Test
9%
Stable COPD
9%
Impaired Swallowing
9%
Therapeutic Outcome
9%
EGFR Exon 20 Insertion mutations
9%
Prognostic Understanding
9%
Immune Inhibition
9%
Japanese Nation
9%
